[Pubmed] Mortality risk in patients with myasthenia gravis

[RSS-Bot]

Front Neurol. 2025 May 14;16:1586031. doi: 10.3389/fneur.2025.1586031. eCollection 2025.

ABSTRACT

INTRODUCTION: Although some reports link Myasthenia Gravis to higher mortality, the evidence remains contradictory and unclear. Real-life data is limited primarily due to challenges in selecting control groups and mitigating bias. Additionally, a revised mortality assessment should be conducted due to recent advancements in Myasthenia Gravis treatments over the past decade, including new biological therapies and the impact of the COVID-19 pandemic from 2020 to 2023.

METHODS: We conducted a retrospective analysis of all patients diagnosed with Myasthenia Gravis at our tertiary center between 2000 and 2023, extracting mortality and clinical features compared to two age- and sex-matched control groups of neurological or rheumatologic patients.

RESULTS: We identified 436 Myasthenic patients and 2,616 controls (1308 in each control group). Myasthenia Gravis mortality was 14% at 5 years (61/422) and 21% at 10 years (87/422). Mortality was significantly higher than control groups (p < 0.001). Intubations during myasthenic crisis were linked to higher mortality (p = 0.002). Bulbar weakness at presentation showed higher mortality but did not reach clinical significance. We compared the mean age at death in MG patients to national life expectancy benchmarks using a one-sample Z-test, revealing significantly younger age at death in both males (78.3 vs. 81.6 years, p = 0.009) and females (76.5 vs. 85.2 years, p < 0.00001). Patients with normal thymic pathology showed better outcomes and lower mortality after thymic removal (p < 0.0001). The primary cause of death was linked to infections, significantly correlated with chronic steroid use.

DISCUSSION: In conclusion, patients with Myasthenia Gravis had higher mortality rates. Thymic removal reduced mortality, while intubation is associated with increased mortality risk.

PMID:40438573 | PMC:PMC12116355 | DOI:10.3389/fneur.2025.1586031


Source: https://pubmed.ncbi.nlm.nih.gov/4043857 ... t9+e462414